患有第二次原发性恶性瘤的肺平细胞癌患者的预后分析:一项SEER数据库研究
Weiqing Han1, Silin Wang2, Lang Su2
1Department of Cardiothoracic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Frontiers in oncology
|March 6, 2024
概括
患有第二种原发性瘤 (LS-SPM) 的肺状细胞癌患者的生存率明显改善. 建议对LS-SPM患者进行积极治疗和免疫监测.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 临床预后 临床预后
背景情况:
- 肺状细胞癌 (LUSC) 患者面临第二次原发性瘤的风险增加,使预后复杂化.
- 评估LUSC患有二次原发性恶性瘤的患者的结果是一个重大的临床挑战.
研究的目的:
- 为了评估肺状细胞癌患者诊断出第二种原发性瘤的预后.
- 为这些患者提供最佳治疗和监测策略的见解.
主要方法:
- 利用来自LUSC患者的监测,流行病学和最终结果 (SEER) 数据库的数据.
- 将患者分为三组:LS-SPM,OT-LUSC和LUSC-only进行比较分析.
- 采用了单变量,分层,多重回归和卡普兰-梅尔生存分析.
主要成果:
- 该研究分析了101,626名LUSC患者,确定了患有第二种原发性瘤 (LS-SPM) 的人的预后有利.
- LS-SPM患者的寿命显著延长,平均存活时间为64个月,平均存活时间为89.11个月.
- 多重回归分析证实LS-SPM患者的生存结果优于LUSC-only和OT-LUSC组.
结论:
- 患有第二种原发性瘤 (LS-SPM) 的肺状细胞癌患者的预后良好.
- 建议对LS-SPM患者采取积极的治疗方法和警的免疫监测.
- 这项研究为LS-SPM的病理生理学和治疗提供了新的视角.
相关概念视频
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
01:25Statistical Methods for Analyzing Epidemiological Data
365
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
365